TLR4 and long COVID-19: One possible therapeutic approach that has shown success in some patients with PASC is treatment with low-dose naltrexone [92], an opioid receptor antagonist that has an immunomodulatory effect via the modulation of Toll-like receptor 4 (TLR4), which signals and counteracts microglial activation [93].